Physician profile
Vahe Badalian
NPI 1477625945
$1,253.72
in general payments reported to CMS, 2019-2025
15 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $65.72 · 2021: $356 · 2022: $242 · 2023: $129 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $309.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $263.73 | 2019-2023 | Brilinta |
| Edwards Lifesciences Corporation | $204.54 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $148.14 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $142.62 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $141.53 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $78.12 | 2019-2023 | Camzyos |
| Pfizer INC. | $66.91 | 2021-2025 | |
| Amgen INC. | $46.54 | 2019-2020 | |
| Boston Scientific Corporation | $38.09 | 2022-2023 | |
| Getinge USA Sales, LLC | $33.31 | 2019 | |
| Abiomed | $22.73 | 2022 | |
| Medtronic, INC. | $19.51 | 2021 | |
| Alnylam Pharmaceuticals INC. | $16.72 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.87 | 2019 | |
| W. L. Gore & Associates, INC. | $15.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vahe Badalian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.